0
No votes yet

The Nurse as Principal Investigator in a Pharmaceutically Sponsored Drug Trial: Considerations and Challenges

Margaret Q. Rosenzweig
Catherine M. Bender
Adam M. Brufsky
ONF 2005, 32(2), 293-299 DOI: 10.1188/05.ONF.293-299

Purpose/Objectives: To discuss the process, considerations, benefits, and challenges of the nurse as principal investigator in a cancer care drug trial.

References 

Artinian, N.T., Froelicher, E.S., & Vander Wal, J.S. (2004). Data and safety monitoring during randomized controlled trials of nursing interventions. <i>Nursing Research, 53</i>, 414-418.

Bodenheimer, T. (2000). Uneasy alliance—Clinical investigators and the pharmaceutical industry. <i>New England Journal of Medicine, 342</i>, 1539-1544.

Clahsen, P.C., van de Velde, J.C., Julien, J.P., Floiras, J.L., & Mignolet, F.Y. (1994). Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. <i>Journal of Clinical Oncology, 12</i>, 1266-1271.

Conn, V.S., Rantz, M.J., Wipke-Tevis, D.D., & Maas, M.L. (2001). Designing effective nursing interventions. <i>Research in Nursing and Health, 24</i>, 433-442.

Ebright, P. (2001). Learning "how to" conduct clinical research from others' experiences. <i>Clinical Nurse Specialist, 15</i>, 284-285.

Ellis, E., Riegel, B., Hamon, M., Carlson, B., Jimenez, S., & Parkington, S. (2001). The challenges of conducting clinical research: One research team's experiences. <i>Clinical Nurse Specialist, 15</i>, 286-294.

Goodnough, L.T., Saito, H., Manni, A., Jones, P.K., & Pearson, O.H. (1984). Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. <i>Cancer, 54</i>, 1264-1268.

Hewitt-Taylor, J. (2002). Evidence-based practice. <i>Nursing Standard, 17</i>(14-15), 47-52.

Levine, M., Hirsh, J., Gent, M., Arnold, A., Warr, D., Falanga, A., et al. (1994). Double-blind randomised trial of very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. <i>Lancet, 343</i>, 886-889.

Lynch, M.P., Cope, D.G., & Murphy-Ende, K. (2001). Advanced practice issues: Results of the ONS Advanced Practice Nursing survey. <i>Oncology Nursing Forum, 28</i>, 1521-1530.

Murray, E., Lo., B., Pollack, L., Donelan, K., & Lee, K. (2004). Direct-to-consumer advertising: Public perceptions of its effects on health behaviors, health care, and the doctor-patient relationship. <i>Journal of the American Board of Family Practice, 17</i>, 6-18.

National Institutes of Health. (1998). NIH policy for data and safety monitoring. Retrieved July 27, 2003, from <a target="_blank" href='http://grants1.nih.gov/grants/guide/index.html'>http://grants1.nih.gov/g...

National Institutes of Health. (2002). <i>State-of-the-science statement on symptom management in cancer: Pain, depression, and fatigue.</i> Bethesda, MD: Author.

Pellino, T.A. (2002). Implementing clinical research: Perils, pitfalls, and planning. <i>Orthopedic Nursing, 21</i>(5), 73-79.

Rosenzweig, M.Q., Bender, C.M., Lucke, J.P., Yasko, J.M., & Brufsky, A.M. (2004). The decision to prematurely terminate a trial of RHuEPO due to thrombotic events. <i>Journal of Pain and Symptom Management, 27</i>, 185-190.

Saphner, T., Tormey, D., & Gray, R. (1991). Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. <i>Journal of Clinical Oncology, 9</i>, 286-294.

U.S. Food and Drug Administration. (2001). Frequently asked questions on drug development and investigational new drug applications. Retrieved February 10, 2005, from <a target="_blank" href='http://www.fda.gov/cder/about/smallbiz/faq.htm#submit%20an%20IND?'>http:...

U.S. Food and Drug Administration. (2002). Investigational new drug application. Selecting investigators and monitors. Retrieved February 10, 2005, from <a target="_blank" href='http://a257.g.akamaitech.net/7/257/2422/14mar20010800/edocket.access.gpo...